Circadian continuous venous infusion of 5-fluoro-2-deoxy-uridine (PUDR) has been used to treat 134 metastatic renal cell carcinomas (RCC) and 14 locally advanced BCC (all N+). All patients underwent radical nephrectomy and did not receive previous chemo- or radiation therapy. The drug was delivered by the Medtronic Synchromed implantable system with the Hrushesky circadian chronobiologic pattern (14-day cycles of CHT alternating with 14-day intervals of heparinized physiologic saline infusion). The minimum follow-up was 6 months, with a range of 6-48 months and a median of 24 months. The range of treatment was between 3 and 36 months. Results showed 58 progressions (43.2%), 11 mixed responses (8.2%), 17 partial responses (12.7%), 8 complete responses (6%) and 40 stable disease (29.9%). The survival rate is about 40% at 1 year and 18% at 2 years. No toxicity was observed in 112 patients (83.6%), mild in 22 patients (16.4%) and severe (lung fibrosis) in 2 patients (1.5%). In the group of locally advanced RCC all patients are disease-free at a mean follow-up of 15 months (range 6-24 months).
|Translated title of the contribution||Continuous infusion of 5-fluoro-2-deoxy-uridine (FUDR) with circadian chronobiologic rhythm in locally advanced metastatic renal tumor (N+ e/o V+)|
|Number of pages||3|
|Journal||Acta Urologica Italica|
|Issue number||SUPPL. 6|
|Publication status||Published - 1992|
ASJC Scopus subject areas